Menu Search
Equities

JOHNSON DRN

JNJB34:SAO

JOHNSON DRN

Actions
  • Price (BRL)50.58
  • Today's Change-0.540 / -1.06%
  • Shares traded4.48k
  • 1 Year change-9.14%
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2024 23:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		JNJ:NYQ since
announced		Transaction
value
Shockwave Medical IncAnnounced05 Apr 202405 Apr 2024Announced-3.72%14.07bn
Ambrx Biopharma IncDeal completed08 Jan 202408 Jan 2024Deal completed-8.88%1.98bn
Data delayed at least 15 minutes, as of Apr 26 2024 00:00 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
BB Gest�o de Recursos DTVM SAas of 31 Dec 2023229.35k0.00%
Ita� Unibanco SAas of 31 Dec 2023165.79k0.00%
Safra Asset Management Ltda.as of 31 Dec 202399.30k0.00%
Bram Bradesco Asset Management S/A DTVMas of 31 Dec 202383.25k0.00%
Caixa DTVM SAas of 31 Dec 202337.42k0.00%
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 31 Dec 20238.66k0.00%
Western Asset Management Company DTVM Ltda.as of 31 Dec 2023380.000.00%
Morgan Stanley Administradora de Carteiras SAas of 31 Dec 202351.000.00%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.